Insider Transactions in Q4 2022 at Athenex, Inc. (ATNX)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
77,288
+1.85%
|
$0
$0.15 P/Share
|
|
Dec 30
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,220
+5.81%
|
$0
$0.15 P/Share
|
|
Dec 30
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,390
+8.59%
|
$0
$0.15 P/Share
|
|
Dec 16
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,223
+11.44%
|
$0
$0.12 P/Share
|
|
Dec 16
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,386
+7.57%
|
$0
$0.12 P/Share
|
|
Dec 16
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
96,284
+2.33%
|
$0
$0.12 P/Share
|
|
Dec 02
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
57,287
+1.44%
|
$0
$0.2 P/Share
|
|
Dec 02
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,623
+5.04%
|
$0
$0.2 P/Share
|
|
Dec 02
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,512
+8.11%
|
$0
$0.2 P/Share
|
|
Nov 18
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
58,762
+1.49%
|
$0
$0.19 P/Share
|
|
Nov 18
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,257
+5.44%
|
$0
$0.19 P/Share
|
|
Nov 18
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,578
+9.04%
|
$0
$0.19 P/Share
|
|
Nov 04
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
58,402
+1.51%
|
$0
$0.2 P/Share
|
|
Nov 04
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,103
+5.72%
|
$0
$0.2 P/Share
|
|
Nov 04
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,561
+9.87%
|
$0
$0.2 P/Share
|
|
Oct 21
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
62,637
+1.64%
|
$0
$0.18 P/Share
|
|
Oct 21
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,923
+6.47%
|
$0
$0.18 P/Share
|
|
Oct 21
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,747
+11.66%
|
$0
$0.18 P/Share
|
|
Oct 07
2022
|
Jinn Wu Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,284
+6.35%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
John Vierling Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,284
+33.32%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
Benson Kwan Hung Tsang Director |
BUY
Grant, award, or other acquisition
|
Direct |
47,737
+32.24%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
Robert J. Spiegel Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,453
+29.54%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
Manson Fok Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,133
+1.49%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
Stephanie A Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,717
+24.15%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,076
+10.31%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,340
+5.32%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
47,323
+1.26%
|
$0
$0.24 P/Share
|